Serina Therapeutics Inc

Bailey Gregory’s March 31 buy of 59,667 shares at $1.94 hints at confidence amid a declining stock, suggesting insiders see hidden value in the company’s cell‑immortality tech.

Insider buy by Serina Therapeutics’ CSO signals confidence amid fresh private placement and leadership change, hinting at potential upside for investors.

Serina Therapeutics insider buying signals renewed confidence amid a 58% rally—insightful analysis of CSO Moreadith Randall’s trade, pipeline milestones, and investor implications.

Serina Therapeutics insider trading: Chief Scientific Officer Moreadith Randall’s 6,500‑share buy‑sell cycle reveals short‑term gains, raising questions on long‑term value and company fundamentals.

Serina Therapeutics insider buy sparks optimism: CSO’s 6,500‑share purchase and soaring social buzz hint at a possible short‑term rally amid valuation risks.

Serina Therapeutics insider trade: CSO Moreadith Randall flips shares at a premium, hinting at short‑term volatility and potential rebound after upcoming news.